The server is busy

Hoop Dreams
05/02/2025 10 min

Listen "The server is busy"

Descargar episodio Ver en sitio original

Episode Synopsis

VYD2311, a monoclonal antibody for COVID-19, is showing promising Phase 1/2 clinical trial results. With a potential half-life exceeding 139 days, it could serve as a long-lasting alternative to vaccination, especially for immunocompromised individuals. However, concerns about its temporary effects and high cost have sparked debates on its feasibility compared to treatments like Paxlovid. Could this antibody change the game for COVID-19 management? For advertising opportunities, visit Avonetics.com.
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA